 Down-Regulation
"Down-Regulation" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.
| Descriptor ID |
D015536
|
| MeSH Number(s) |
G02.111.240 G05.308.200 G07.690.773.937
|
| Concept/Terms |
Down-Regulation- Down-Regulation
- Down Regulation
- Downregulation
- Down-Regulation (Physiology)
|
Below are MeSH descriptors whose meaning is more general than "Down-Regulation".
Below are MeSH descriptors whose meaning is more specific than "Down-Regulation".
This graph shows the total number of publications written about "Down-Regulation" by people in this website by year, and whether "Down-Regulation" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 1 | 1 | 2 | | 1992 | 1 | 3 | 4 | | 1993 | 0 | 4 | 4 | | 1994 | 0 | 3 | 3 | | 1995 | 1 | 4 | 5 | | 1996 | 0 | 2 | 2 | | 1997 | 1 | 5 | 6 | | 1998 | 4 | 6 | 10 | | 1999 | 0 | 6 | 6 | | 2000 | 2 | 8 | 10 | | 2001 | 3 | 9 | 12 | | 2002 | 0 | 16 | 16 | | 2003 | 4 | 15 | 19 | | 2004 | 7 | 21 | 28 | | 2005 | 2 | 17 | 19 | | 2006 | 4 | 26 | 30 | | 2007 | 4 | 16 | 20 | | 2008 | 4 | 24 | 28 | | 2009 | 4 | 24 | 28 | | 2010 | 5 | 22 | 27 | | 2011 | 6 | 16 | 22 | | 2012 | 4 | 20 | 24 | | 2013 | 5 | 20 | 25 | | 2014 | 0 | 14 | 14 | | 2015 | 4 | 13 | 17 | | 2016 | 3 | 18 | 21 | | 2017 | 5 | 29 | 34 | | 2018 | 0 | 12 | 12 | | 2019 | 2 | 12 | 14 | | 2020 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Down-Regulation" by people in Profiles.
-
Akhade AS, Atif SM, Lakshmi BS, Dikshit N, Hughes KT, Qadri A, Subramanian N. Type 1 interferon-dependent repression of NLRC4 and iPLA2 licenses down-regulation of Salmonella flagellin inside macrophages. Proc Natl Acad Sci U S A. 2020 11 24; 117(47):29811-29822.
-
Angeletti A, Cantarelli C, Petrosyan A, Andrighetto S, Budge K, D'Agati VD, Hartzell S, Malvi D, Donadei C, Thurman JM, Galešic-Ljubanovic D, He JC, Xiao W, Campbell KN, Wong J, Fischman C, Manrique J, Zaza G, Fiaccadori E, La Manna G, Fribourg M, Leventhal J, Da Sacco S, Perin L, Heeger PS, Cravedi P. Loss of decay-accelerating factor triggers podocyte injury and glomerulosclerosis. J Exp Med. 2020 09 07; 217(9).
-
McDaniel CT, Panmanee W, Winsor GL, Gill E, Bertelli C, Schurr MJ, Dongare P, Paul AT, Ko SB, Lau GW, Dasgupta N, Bogue AL, Miller WE, Mortensen JE, Haslam DB, Dexheimer P, Muruve DA, Aronow BJ, Forbes MDE, Danilczuk M, Brinkman FSL, Hancock REW, Meyer TJ, Hassett DJ. AB569, a nontoxic chemical tandem that kills major human pathogenic bacteria. Proc Natl Acad Sci U S A. 2020 03 03; 117(9):4921-4930.
-
Song R, Zhai Y, Ao L, Fullerton DA, Meng X. MicroRNA-204 Deficiency in Human Aortic Valves Elevates Valvular Osteogenic Activity. Int J Mol Sci. 2019 Dec 20; 21(1).
-
Bjorkman KK, Buvoli M, Pugach EK, Polmear MM, Leinwand LA. miR-1/206 downregulates splicing factor Srsf9 to promote C2C12 differentiation. Skelet Muscle. 2019 12 02; 9(1):31.
-
Yang C, McDermot DS, Pasricha S, Brown AS, Bedoui S, Lenz LL, van Driel IR, Hartland EL. IFN? receptor down-regulation facilitates Legionella survival in alveolar macrophages. J Leukoc Biol. 2020 02; 107(2):273-284.
-
Schmidt AF, Holmes MV, Preiss D, Swerdlow DI, Denaxas S, Fatemifar G, Faraway R, Finan C, Valentine D, Fairhurst-Hunter Z, Hartwig FP, Horta BL, Hypponen E, Power C, Moldovan M, van Iperen E, Hovingh K, Demuth I, Norman K, Steinhagen-Thiessen E, Demuth J, Bertram L, Lill CM, Coassin S, Willeit J, Kiechl S, Willeit K, Mason D, Wright J, Morris R, Wanamethee G, Whincup P, Ben-Shlomo Y, McLachlan S, Price JF, Kivimaki M, Welch C, Sanchez-Galvez A, Marques-Vidal P, Nicolaides A, Panayiotou AG, Onland-Moret NC, van der Schouw YT, Matullo G, Fiorito G, Guarrera S, Sacerdote C, Wareham NJ, Langenberg C, Scott RA, Luan J, Bobak M, Malyutina S, Pajak A, Kubinova R, Tamosiunas A, Pikhart H, Grarup N, Pedersen O, Hansen T, Linneberg A, Jess T, Cooper J, Humphries SE, Brilliant M, Kitchner T, Hakonarson H, Carrell DS, McCarty CA, Lester KH, Larson EB, Crosslin DR, de Andrade M, Roden DM, Denny JC, Carty C, Hancock S, Attia J, Holliday E, Scott R, Schofield P, O'Donnell M, Yusuf S, Chong M, Pare G, van der Harst P, Said MA, Eppinga RN, Verweij N, Snieder H, Christen T, Mook-Kanamori DO, Gustafsson S, Lind L, Ingelsson E, Pazoki R, Franco O, Hofman A, Uitterlinden A, Dehghan A, Teumer A, Baumeister S, Dörr M, Lerch MM, Völker U, Völzke H, Ward J, Pell JP, Meade T, Christophersen IE, Maitland-van der Zee AH, Baranova EV, Young R, Ford I, Campbell A, Padmanabhan S, Bots ML, Grobbee DE, Froguel P, Thuillier D, Roussel R, Bonnefond A, Cariou B, Smart M, Bao Y, Kumari M, Mahajan A, Hopewell JC, Seshadri S, Dale C, Costa RPE, Ridker PM, Chasman DI, Reiner AP, Ritchie MD, Lange LA, Cornish AJ, Dobbins SE, Hemminki K, Kinnersley B, Sanson M, Labreche K, Simon M, Bondy M, Law P, Speedy H, Allan J, Li N, Went M, Weinhold N, Morgan G, Sonneveld P, Nilsson B, Goldschmidt H, Sud A, Engert A, Hansson M, Hemingway H, Asselbergs FW, Patel RS, Keating BJ, Sattar N, Houlston R, Casas JP, Hingorani AD. Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9. BMC Cardiovasc Disord. 2019 10 29; 19(1):240.
-
Haarhaus M, Ray KK, Nicholls SJ, Schwartz GG, Kulikowski E, Johansson JO, Sweeney M, Halliday C, Lebioda K, Wong N, Brandenburg V, Beddhu S, Tonelli M, Zoccali C, Kalantar-Zadeh K. Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular disease. Atherosclerosis. 2019 11; 290:59-65.
-
Vallejo-Vaz AJ, Ray KK, Ginsberg HN, Davidson MH, Eckel RH, Lee LV, Bessac L, Pordy R, Letierce A, Cannon CP. Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control. Atherosclerosis. 2019 09; 288:85-93.
-
Ray KK, Vallejo-Vaz AJ, Ginsberg HN, Davidson MH, Louie MJ, Bujas-Bobanovic M, Minini P, Eckel RH, Cannon CP. Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials. Atherosclerosis. 2019 09; 288:194-202.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|